

## MilliporeSigma, GenScript to stimulate cell and gene therapy industrialization in China

20 March 2019 | News

### Collaboration to build global-standard platform for plasmid and virus manufacturing in China



MilliporeSigma signs a non-binding Memorandum of Understanding with GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing.

The parties envision an alliance that will accelerate the industrialization and commercialization of cell and gene therapy in China. GenScript, a leading biotech company headquartered in Nanjing, China, aims to create a global-standard platform of plasmid and virus manufacturing service in the country.

MilliporeSigma plans to provide GenScript with comprehensive products, training and consulting services covering process design, facility concept design and quality management system set-up from lab development to large-scale GMP manufacturing.

MilliporeSigma is among only a few manufacturers that have an industrialized process to make viral vectors. To create personalized therapy products, genes are delivered into immune cells using viral vectors, such as the ones that MilliporeSigma makes. The company offers a unique combination as a contract manufacturing organization, serving other companies to provide services, and as a bioprocess manufacturing equipment maker.

A confluence of demand, growth and subsequent need to scale the cell and gene therapy market in China is an important driver for MilliporeSigma to deliver its expertise to this region. According to [clinicaltrials.gov](http://clinicaltrials.gov), China is the world-leader in terms of where gene-modified cell therapy clinical trials are conducted. Today, more than 130 companies in China are developing cell and gene therapies ranging from chimeric antigen receptor T cell therapy (CAR-T) / T cell receptor therapy (TCR-T) and adeno-associated virus (AAV) to oncolytic virus.

MilliporeSigma plans to provide a complete set of process products, services and staff training to support GenScript in building a world-class plasmid and viral vector manufacture platform to accelerate the industrialization of cell and gene therapy in China.